• PDF / 169,229 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 81 Downloads / 146 Views

DOWNLOAD

REPORT

---

1 S

Myelotoxicity: case report In a retrospective study of 12 patients conducted between June 2010 and March 2016, a 72-year-old man* was described, who developed myelotoxicity during treatment with cetuximab and carboplatin for cutaneous squamous cell cancer (cSCC). The man, who had cSCC, received five cycles of cetuximab in association with carboplatin every 3 weeks [route and dosage not stated]. He tolerated the treatment, except for grade III myelotoxicity [time to reaction onset and outcome not stated]. Following this treatment, a partial response was achieved cSCC with clinical benefits in terms of pain. Thereafter, he received radiotherapy with progression-free survival (PFS) of 9.5 months. * Age and sex of the patient were obtained via personal communication with the author. Galbiati D, et al. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Drugs in Context 8: 212611, 2019. Available 803498226 from: URL: http://doi.org/10.7573/DIC.212611

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819